Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SARS-CoV-2 s-protein based vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: BVX-0320

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Biovaxys

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 15, 2021

            Details:

            Under the terms of the agreement, WuXi Bio will synthesize high yields of fully characterized, Good Laboratory Practice (GLP) grade SARS-CoV-2 s-protein required by BioVaxys for BVX-0320, its COVID-19 vaccine candidate, and for its Covid-T™ immunodiagnostic program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AS1411

            Therapeutic Area: Infections and Infectious Diseases Product Name: AS1411

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Qualigen Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 05, 2020

            Details:

            Qualigen Therapeutics has signed a contract with STA Pharmaceutical, a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen's lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HLX71

            Therapeutic Area: Infections and Infectious Diseases Product Name: HLX71

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 13, 2020

            Details:

            The Company actively involves in development of anti-COVID-19 drugs with two candidates in pre-clinical phase, including HLX71 (S1 protein), and HLX70 (S1 protein).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Inactivated vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Institut of Butantan

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 11, 2020

            Details:

            This collaboration focuses on the clinical development to advance the clinical trials of CoronaVac, Sinovac’s inactivated vaccine candidate against COVID-19 to Phase III.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 S-Trimer

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: CEPI

            Deal Size: $3.5 million Upfront Cash: Undisclosed

            Deal Type: Funding April 27, 2020

            Details:

            CEPI to provide funds to Clover Biopharmaceuticals Australia to support preparation and initiation of a phase 1 trial of Clover’s protein-based COVID-19 S-Trimer vaccine in Australia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 17, 2020

            Details:

            The pilot testing of the vaccine for novel coronavirus, will be focused on animal toxicology and the vaccine's effectiveness. Clinical trials are expected to start in mid-April.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19 S-Trimer

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: GlaxoSmithKline

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 24, 2020

            Details:

            GSK will provide Clover with its pandemic adjuvant system for further evaluation of S-Trimer in preclinical studies.